대구교차로를 시작페이지로
신문대구교차로 원룸 부동산몰 자동차몰 교차로매거진 구인구직 이벤트룸
  2018.11.17. 토요일
사회·경제 정치 부동산 문화·생활 연예 라이프   사랑나눔 캠페인
뉴스홈 > 문화/생활 > 건강과학
Acelity Enters Agreement to Transition Systagenix Manufacturing Facility to Scapa Healthcare
| 기사입력 : 2018-09-14 15:00


Today, Acelity announced an agreement to sell its advanced wound dressings manufacturing facility located in Gargrave, England, to Scapa Healthcare. In conjunction with the transfer of the facility upon close of the transaction, more than 350 employees will transition to Scapa in support of a manufacturing agreement with KCI, an Acelity Company. The manufacturing agreement will assure continued supply of key products and components which advance KCI’s global growth strategy in advanced wound dressings (AWD).

Upon completion of the transaction, the manufacturing operations, sterilization services, warehouse facilities, R&D and regulatory support functions in Gargrave, England, will be transferred to Scapa Healthcare.

Building upon the momentum of the Company’s recent acquisition of Crawford Healthcare, this strategic transaction allows KCI to further enhance its position as a global leader in advanced wound care. The transfer of the Gargrave facility enables KCI to rely upon Scapa’s manufacturing expertise on key product lines, while enhancing KCI’s focus on marketing and commercializing the growing AWD business.

“The global advanced wound care market is large and growing rapidly. Expanding the KCI AWD dressing portfolio, including the market-leading collagen dressing PROMOGRAN PRISMA™ Matrix and super-absorbent KerraMax Care? range, to further complement our negative pressure wound therapy products is imperative to our growth objectives,” said R. Andrew Eckert, President and CEO of Acelity. “This transaction will allow us to maintain and increase our innovation and product development efforts, as well as focus on the commercial execution of our AWD business, while we strategically invest to expand in other areas, such as our leading digital wound care and surgical solutions.”

Until the transaction is finalized, Acelity will continue to manage the Gargrave facility. Acelity anticipates closing the transaction early October 2018.

About Acelity

Acelity L.P. Inc. is a global advanced wound care company committed to developing innovative healing solutions for customers and patients across the care continuum. Its subsidiary, KCI, is the most trusted brand in advanced wound care. The unsurpassed KCI product portfolio is available in more than 90 countries and delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005333/en/

언론연락처:Acelity Kathryn Skeen Corporate Communications +1-210-882-2067 Jathan Tucker Investor Relations +1-210-255-6816

이 뉴스는 기업·기관이 발표한 보도자료 전문입니다.

출처 : Acelity L.P. Inc.

본 보도자료는 에서 제공합니다.
서울시, ‘수험표 제시하면 한강..
GSMA, 독일의 5G 주파수 ..
GSMA Welcomes Ger..
조호, 고객경험 플랫폼 분야에서..
조호, 조호 소셜 업데이트 발표..
조호, 데이터블렌딩과 AI 강점..
Zoho Deepens Anal..
Richer Analytics ..
Zoho Analytics Em..
중국 최고의 하이테크 전시회 C..
[]  
[]  
  고객센터  |  회사소개  |  자주묻는질문  |  제휴문의  |  배너광고문의  |  개인정보 취급방침  |  청소년 보호정책  |  사이트맵 |  원격지원
Copyright ⓒ 1999 ㈜교차로 All right reserved.